metformin and Neoplasm Metastasis studies

Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.

Neoplasm Metastasis: The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.

Research Excerpts

Excerpt	Relevance	Reference
"After a comprehensive literature search, only three phase 2 RCTs on the use of metformin as adjunctive therapy for locally advanced and metastatic breast cancer were included."	9.12	A systematic review and meta-analysis on the efficacy and safety of metformin as adjunctive therapy among women with metastatic breast cancer. ( Eugenio, KPY; Jimeno, CA; Lusica, PMM; Sacdalan, DBL, 2021)
"Antimetastatic effect of Metformin has been documented in epithelial ovarian cancer (EOC)."	8.02	Roles of metformin-mediated girdin expression in metastasis of epithelial ovarian cancer. ( Dang, J; Gao, J; Hu, D; Jin, Z; Li, L; Li, W; Liu, X; Luo, Y; Ma, F; Sun, H; Wang, D; Wang, J, 2021)
" In this in vitro study, we hypothesized that metformin with an effective dose can inhibit tumor cell proliferation and metastasis by modulating the expressions of MMP-2 and -9 and interfering with NF-kB signaling in primary breast cancer cells (PBCCs)."	8.02	Anti-cancer effect of metformin on the metastasis and invasion of primary breast cancer cells through mediating NF-kB activity. ( Besli, N; Dilek Kancagi, D; Ekmekci, CG; Kanigur Sultuybek, G; Karagulle, OO; Ovali, E; Senol, K; Soydas, T; Tastan, C; Tuncdemir, M; Ulutin, T; Yaprak Sarac, E; Yenmis, G; Yilanci, M, 2021)
"Accumulating evidence suggests that metformin reduces the incidence and mortality of colorectal cancer (CRC)."	7.96	Metformin changes the immune microenvironment of colorectal cancer in patients with type 2 diabetes mellitus. ( Horie, H; Kawahira, H; Kitayama, J; Koinuma, K; Lefor, AK; Mimura, T; Ohzawa, H; Saito, A; Sata, N; Yamaguchi, H, 2020)
"The use of metformin and incretins in women with T2DM and BC may reduce the risk of metastases."	7.83	Impact of metformin on metastases in patients with breast cancer and type 2 diabetes. ( Jacob, L; Kalder, M; Kostev, K; Rathmann, W, 2016)
"Sorafenib is recognized as a standard treatment for advanced hepatocellular carcinoma (HCC)."	7.83	Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models. ( Cao, M; Cui, Y; Fang, F; Gao, J; Guo, Z; Li, H; Li, Q; Song, T; Sun, H; Yin, H; You, A; Zhang, T; Zhang, W; Zhou, H; Zhu, X; Zuo, B, 2016)
"We previously found that a low dose of sorafenib had a prometastatic effect on hepatocellular carcinoma (HCC), which was caused by downregulation of TIP30 expression."	7.83	Metformin inhibits the prometastatic effect of sorafenib in hepatocellular carcinoma by upregulating the expression of TIP30. ( Cao, M; Cui, Y; Fang, F; Gao, J; Guo, Z; Li, H; Li, Q; Song, T; Sun, H; You, A; Zhang, T; Zhang, W; Zhou, H; Zhu, X, 2016)
"Metformin can induce breast cancer (BC) cell apoptosis and reduce BC local and metastatic growth in preclinical models."	7.83	Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells. ( Albini, A; Bertolini, F; Calleri, A; Dallaglio, K; Gregato, G; Labanca, V; Mancuso, P; Noonan, DM; Orecchioni, S; Reggiani, F; Rossi, T; Talarico, G, 2016)
"Metformin use has recently been observed to decrease both the rate and mortality of breast cancer."	7.81	Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes. ( Ahn, SH; Kim, HJ; Koh, BS; Kwon, H; Lee, JW; Lee, SB; Lee, Y; Park, HS; Sohn, G; Son, BH; Yu, JH, 2015)
" Importantly, metformin inhibited tumor growth and distant metastases in tumor-bearing nude mice and reversed IL-6-induced EMT both in vitro and in vivo."	7.80	Metformin inhibits the IL-6-induced epithelial-mesenchymal transition and lung adenocarcinoma growth and metastasis. ( Cheng, X; Han, R; He, L; He, Y; Li, L; Long, H; Wang, Y; Xiang, T; Zhao, Z; Zhu, B, 2014)
" We recently established a pre-clinical model of estrogen-dependent MCF-7 breast cancer cells that were chronically adapted to grow (> 10 months) in the presence of graded, millimolar concentrations of the anti-diabetic biguanide metformin, an AMPK agonist/mTOR inhibitor that has been evaluated in multiple in vitro and in vivo cancer studies and is now being tested in clinical trials."	7.80	Acquired resistance to metformin in breast cancer cells triggers transcriptome reprogramming toward a degradome-related metastatic stem-like profile. ( Corominas-Faja, B; Cuyàs, E; Fernández-Arroyo, S; Joven, J; Martin-Castillo, B; Menendez, JA; Oliveras-Ferraros, C; Rodríguez-Gallego, E; Vazquez-Martin, A, 2014)
"While overall there was no statistically significant association between metformin exposure and disseminated colorectal cancer at diagnosis, there was a suggestion that high intensity, exclusive metformin use may be associated with reduced odds of disseminated disease."	7.80	Metformin exposure and disseminated disease in patients with colorectal cancer. ( Barron, TI; Bennett, K; Sharp, L; Spillane, S, 2014)
"Metformin was reported to inhibit the proliferation of many cancer cells, including melanoma cells."	7.79	Metformin blocks melanoma invasion and metastasis development in AMPK/p53-dependent manner. ( Abbe, P; Allegra, M; Bahadoran, P; Ballotti, R; Bertolotto, C; Cerezo, M; Giacchero, D; Lehraiki, A; Ohanna, M; Rocchi, S; Rouaud, F; Tartare-Deckert, S; Tichet, M, 2013)
"The growth and metastasis of MDA-MB-231 breast cancer may be inhibited by metformin."	7.79	Multimodality imaging assessments of response to metformin therapy for breast cancer in nude mice. ( Gao, FB; Mao, Y; Wang, L; Wang, YQ; Xia, R, 2013)
"Bone metastasis is a common impairment associated with advanced breast cancer."	5.72	Effects of metformin on human bone-derived mesenchymal stromal cell-breast cancer cell line interactions. ( Hamilton, G; Lang, C; Moser, D; Neumayer, C; Plangger, A; Radtke, C; Rath, B; Staud, C; Teufelsbauer, M, 2022)
"Metformin has been confirmed to suppress invasion and migration of various types of cancer."	5.72	Metformin inhibits melanoma cell metastasis by suppressing the miR-5100/SPINK5/STAT3 axis. ( Jianping, K; Jianqiang, W; Suwei, D; Xiang, M; Yanbin, X; Yunqing, W; Zhen, L; Zhuohui, P, 2022)
"Metformin (MTF) has been reported to target NLK (Nemo-like kinase) to inhibit non-small lung cancer cells."	5.48	Metformin Enhances the Effect of Regorafenib and Inhibits Recurrence and Metastasis of Hepatic Carcinoma After Liver Resection via Regulating Expression of Hypoxia Inducible Factors 2α (HIF-2α) and 30 kDa HIV Tat-Interacting Protein (TIP30). ( Guo, X; Yang, L; Yang, Q, 2018)
"Metformin attenuates the metastasis and autophagy in osteosarcoma."	5.48	Inhibition of LCMR1 and ATG12 by demethylation-activated miR-570-3p is involved in the anti-metastasis effects of metformin on human osteosarcoma. ( Bao, X; Guan, H; Li, F; Zhao, L, 2018)
"102 women with newly diagnosed breast cancer were divided into 2 main groups, a control group and a metformin group."	5.43	Metformin may protect nondiabetic breast cancer women from metastasis. ( El-Bassiouny, NA; El-Haggar, SM; El-Shitany, NA; Mostafa, MF, 2016)
"Metformin is an oral drug that has been widely used to treat type 2 diabetes mellitus."	5.42	Metformin inhibits the proliferation, metastasis, and cancer stem-like sphere formation in osteosarcoma MG63 cells in vitro. ( Chen, X; Hu, C; Hu, F; Shen, Y; Wang, J; Yu, P; Zhang, W, 2015)
"After a comprehensive literature search, only three phase 2 RCTs on the use of metformin as adjunctive therapy for locally advanced and metastatic breast cancer were included."	5.12	A systematic review and meta-analysis on the efficacy and safety of metformin as adjunctive therapy among women with metastatic breast cancer. ( Eugenio, KPY; Jimeno, CA; Lusica, PMM; Sacdalan, DBL, 2021)
" In this in vitro study, we hypothesized that metformin with an effective dose can inhibit tumor cell proliferation and metastasis by modulating the expressions of MMP-2 and -9 and interfering with NF-kB signaling in primary breast cancer cells (PBCCs)."	4.02	Anti-cancer effect of metformin on the metastasis and invasion of primary breast cancer cells through mediating NF-kB activity. ( Besli, N; Dilek Kancagi, D; Ekmekci, CG; Kanigur Sultuybek, G; Karagulle, OO; Ovali, E; Senol, K; Soydas, T; Tastan, C; Tuncdemir, M; Ulutin, T; Yaprak Sarac, E; Yenmis, G; Yilanci, M, 2021)
"Antimetastatic effect of Metformin has been documented in epithelial ovarian cancer (EOC)."	4.02	Roles of metformin-mediated girdin expression in metastasis of epithelial ovarian cancer. ( Dang, J; Gao, J; Hu, D; Jin, Z; Li, L; Li, W; Liu, X; Luo, Y; Ma, F; Sun, H; Wang, D; Wang, J, 2021)
"Accumulating evidence suggests that metformin reduces the incidence and mortality of colorectal cancer (CRC)."	3.96	Metformin changes the immune microenvironment of colorectal cancer in patients with type 2 diabetes mellitus. ( Horie, H; Kawahira, H; Kitayama, J; Koinuma, K; Lefor, AK; Mimura, T; Ohzawa, H; Saito, A; Sata, N; Yamaguchi, H, 2020)
"Metformin, a first-line drug used to treat type 2 diabetes, has also been shown to have anticancer effects against a variety of malignancies, including colorectal cancer."	3.88	Anti-metastatic effect of metformin via repression of interleukin 6-induced epithelial-mesenchymal transition in human colon cancer cells. ( Kang, MH; Kang, S; Kim, BR; Kim, DY; Lee, DH; Min, BW; Oh, SC; Um, JW, 2018)
"We previously found that a low dose of sorafenib had a prometastatic effect on hepatocellular carcinoma (HCC), which was caused by downregulation of TIP30 expression."	3.83	Metformin inhibits the prometastatic effect of sorafenib in hepatocellular carcinoma by upregulating the expression of TIP30. ( Cao, M; Cui, Y; Fang, F; Gao, J; Guo, Z; Li, H; Li, Q; Song, T; Sun, H; You, A; Zhang, T; Zhang, W; Zhou, H; Zhu, X, 2016)
"Metformin can induce breast cancer (BC) cell apoptosis and reduce BC local and metastatic growth in preclinical models."	3.83	Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells. ( Albini, A; Bertolini, F; Calleri, A; Dallaglio, K; Gregato, G; Labanca, V; Mancuso, P; Noonan, DM; Orecchioni, S; Reggiani, F; Rossi, T; Talarico, G, 2016)
"The use of metformin and incretins in women with T2DM and BC may reduce the risk of metastases."	3.83	Impact of metformin on metastases in patients with breast cancer and type 2 diabetes. ( Jacob, L; Kalder, M; Kostev, K; Rathmann, W, 2016)
"Sorafenib is recognized as a standard treatment for advanced hepatocellular carcinoma (HCC)."	3.83	Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models. ( Cao, M; Cui, Y; Fang, F; Gao, J; Guo, Z; Li, H; Li, Q; Song, T; Sun, H; Yin, H; You, A; Zhang, T; Zhang, W; Zhou, H; Zhu, X; Zuo, B, 2016)
"Metformin use has recently been observed to decrease both the rate and mortality of breast cancer."	3.81	Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes. ( Ahn, SH; Kim, HJ; Koh, BS; Kwon, H; Lee, JW; Lee, SB; Lee, Y; Park, HS; Sohn, G; Son, BH; Yu, JH, 2015)
" The antidiabetic drug metformin has been shown to display antitumoral properties in prostate cancer cell and animal models; however, its role in the formation of metastases remains poorly documented."	3.81	Inhibition of the GTPase Rac1 mediates the antimigratory effects of metformin in prostate cancer cells. ( Ader, I; Bost, F; Cormont, M; Cuvillier, O; Dirat, B; Golzio, M; Larbret, F; Laurent, K; Lemichez, E; Malavaud, B; Massa, F; Mettouchi, A; Tanti, JF, 2015)
" Importantly, metformin inhibited tumor growth and distant metastases in tumor-bearing nude mice and reversed IL-6-induced EMT both in vitro and in vivo."	3.80	Metformin inhibits the IL-6-induced epithelial-mesenchymal transition and lung adenocarcinoma growth and metastasis. ( Cheng, X; Han, R; He, L; He, Y; Li, L; Long, H; Wang, Y; Xiang, T; Zhao, Z; Zhu, B, 2014)
" We recently established a pre-clinical model of estrogen-dependent MCF-7 breast cancer cells that were chronically adapted to grow (> 10 months) in the presence of graded, millimolar concentrations of the anti-diabetic biguanide metformin, an AMPK agonist/mTOR inhibitor that has been evaluated in multiple in vitro and in vivo cancer studies and is now being tested in clinical trials."	3.80	Acquired resistance to metformin in breast cancer cells triggers transcriptome reprogramming toward a degradome-related metastatic stem-like profile. ( Corominas-Faja, B; Cuyàs, E; Fernández-Arroyo, S; Joven, J; Martin-Castillo, B; Menendez, JA; Oliveras-Ferraros, C; Rodríguez-Gallego, E; Vazquez-Martin, A, 2014)
"While overall there was no statistically significant association between metformin exposure and disseminated colorectal cancer at diagnosis, there was a suggestion that high intensity, exclusive metformin use may be associated with reduced odds of disseminated disease."	3.80	Metformin exposure and disseminated disease in patients with colorectal cancer. ( Barron, TI; Bennett, K; Sharp, L; Spillane, S, 2014)
"Metformin was reported to inhibit the proliferation of many cancer cells, including melanoma cells."	3.79	Metformin blocks melanoma invasion and metastasis development in AMPK/p53-dependent manner. ( Abbe, P; Allegra, M; Bahadoran, P; Ballotti, R; Bertolotto, C; Cerezo, M; Giacchero, D; Lehraiki, A; Ohanna, M; Rocchi, S; Rouaud, F; Tartare-Deckert, S; Tichet, M, 2013)
"The growth and metastasis of MDA-MB-231 breast cancer may be inhibited by metformin."	3.79	Multimodality imaging assessments of response to metformin therapy for breast cancer in nude mice. ( Gao, FB; Mao, Y; Wang, L; Wang, YQ; Xia, R, 2013)
"Metformin has been shown to have antitumor effects via a variety of insulin-dependent and insulin-independent mechanisms and to be potentially synergistic with chemotherapy."	2.87	A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy-Naïve Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer. ( Brahmer, JR; Coleman, B; Ettinger, DS; Forde, PM; Gabrielson, E; Hann, CL; Kelly, RJ; Marrone, KA; Purtell, M; Rosner, GL; Zhou, X, 2018)
"Bone metastasis is a common impairment associated with advanced breast cancer."	1.72	Effects of metformin on human bone-derived mesenchymal stromal cell-breast cancer cell line interactions. ( Hamilton, G; Lang, C; Moser, D; Neumayer, C; Plangger, A; Radtke, C; Rath, B; Staud, C; Teufelsbauer, M, 2022)
"Metformin has been confirmed to suppress invasion and migration of various types of cancer."	1.72	Metformin inhibits melanoma cell metastasis by suppressing the miR-5100/SPINK5/STAT3 axis. ( Jianping, K; Jianqiang, W; Suwei, D; Xiang, M; Yanbin, X; Yunqing, W; Zhen, L; Zhuohui, P, 2022)
"KRas is frequently mutated in pancreatic cancers."	1.62	GSK-3β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals. ( Abrams, SL; Akula, SM; Candido, S; Cervello, M; Cocco, L; Duda, P; Falzone, L; Gizak, A; Libra, M; Martelli, AM; McCubrey, JA; Meher, AK; Montalto, G; Rakus, D; Ratti, S; Ruvolo, P; Steelman, LS, 2021)
"Metformin has been documented in epidemiological studies to mitigate tumor progression."	1.56	Metformin Inhibits Tumor Metastasis through Suppressing Hsp90α Secretion in an AMPKα1-PKCγ Dependent Manner. ( Feng, S; Fu, Y; Gong, Y; Jiang, Y; Luo, Y; Wang, C; Zhang, S, 2020)
"EMTs facilitate bladder cancer (BC) metastasis development, but the mechanism by which high-glucose levels promote these EMTs in BC remains unclear."	1.56	Glucose promotes epithelial-mesenchymal transitions in bladder cancer by regulating the functions of YAP1 and TAZ. ( Chen, H; Li, S; Lin, Q; Xia, J; Xu, R; Zhang, F; Zhu, H, 2020)
"Type 2 diabetes mellitus is associated with pNET metastasis and not an independent risk factor for poor prognosis in pNETs."	1.56	Diabetes Is Associated With the Metastasis of Pancreatic Neuroendocrine Tumors. ( Cheng, H; Fan, K; Fan, Z; Gong, Y; Huang, Q; Jin, K; Liu, C; Luo, G; Ni, Q; Yang, C; Yu, X, 2020)
"Metformin-treated mice exhibited suppressed intraperitoneal tumor growth and extended survival, and these effects were lost in mice with severe combined immunodeficiency."	1.51	Metformin Prevents Peritoneal Dissemination ( Eguchi, S; Hirayama, T; Kanetaka, K; Kobayashi, S; Matsuo, M; Nagata, Y; Nishida, M; Udono, H; Yoneda, A, 2019)
"Metformin displays antimigration effects in cervical cancer cells by inhibiting filopodia and lamellipodia formation through the suppression of FAK, Akt and its downstream Rac1 and RhoA protein."	1.51	Metformin Inhibit Cervical Cancer Migration by Suppressing the FAK/Akt Signaling Pathway. ( Chonpathompikunlert, P; Hakimee, H; Hutamekalin, P; Sukketsiri, W; Tanasawet, S; Tipmanee, V, 2019)
"Treatment with metformin did not result in any apparent improvement in time to BF, time to metastasis detection or OS, but there was a 1."	1.51	Metformin may offer no protective effect in men undergoing external beam radiation therapy for prostate cancer. ( Baldwin, G; Bolton, D; Ischia, J; Patel, O; Ranasinghe, WKB; Sengupta, S; Shulkes, A; Wetherell, D; Williams, S, 2019)
"Metastasis is the major cause of high mortality in cancer patients; thus, blocking the metastatic process is of critical importance for cancer treatments."	1.51	Metformin and Docosahexaenoic Acid Hybrid Micelles for Premetastatic Niche Modulation and Tumor Metastasis Suppression. ( Chen, J; Chen, L; Chen, Y; Gao, X; Gu, X; Huang, Y; Jiang, T; Liang, K; Liu, S; Lu, H; Ma, F; Pei, Y; Song, Q; Wang, J; Xu, M; Zhou, S, 2019)
"Metformin attenuates the metastasis and autophagy in osteosarcoma."	1.48	Inhibition of LCMR1 and ATG12 by demethylation-activated miR-570-3p is involved in the anti-metastasis effects of metformin on human osteosarcoma. ( Bao, X; Guan, H; Li, F; Zhao, L, 2018)
"Hypoglycemia is associated with local invasion and angiogenesis, whereas hyperglycemia promotes metastatic colonization."	1.48	Glycemic Variability Promotes Both Local Invasion and Metastatic Colonization by Pancreatic Ductal Adenocarcinoma. ( Akkan, J; Benitz, S; Bruns, P; Ceyhan, GO; Cheng, T; Friess, H; Hofmann, T; Huang, P; Jäger, C; Jastroch, M; Jian, Z; Kleeff, J; Kleigrewe, K; Kong, B; Lamp, D; Maeritz, N; Michalski, CW; Nie, S; Raulefs, S; Shen, S; Shi, K; Steiger, K; Zhang, Z; Zou, X, 2018)
"Metformin (MTF) has been reported to target NLK (Nemo-like kinase) to inhibit non-small lung cancer cells."	1.48	Metformin Enhances the Effect of Regorafenib and Inhibits Recurrence and Metastasis of Hepatic Carcinoma After Liver Resection via Regulating Expression of Hypoxia Inducible Factors 2α (HIF-2α) and 30 kDa HIV Tat-Interacting Protein (TIP30). ( Guo, X; Yang, L; Yang, Q, 2018)
"Defining the mechanisms underlying PCa metastasis may lead to insights into how to decrease morbidity and mortality in this disease."	1.48	Glyoxalase 1 sustains the metastatic phenotype of prostate cancer cells via EMT control. ( Antognelli, C; Cecchetti, R; Peirce, MJ; Riuzzi, F; Talesa, VN, 2018)
"Metformin is an antidiabetic drug used in treatment of type 2 diabetes."	1.46	Metformin inhibits gastric cancer cells metastatic traits through suppression of epithelial-mesenchymal transition in a glucose-independent manner. ( Shamsara, M; Valaee, S; Yaghoobi, MM, 2017)
"Metastasis is the main problem in successful treatment of many types of cancer such as melanoma."	1.46	Preparation and characterization of metformin surface modified cellulose nanofiber gel and evaluation of its anti-metastatic potentials. ( Akbari, V; Nurani, M; Taheri, A, 2017)
"The anticancer properties of ursolic acid (UA) and metformin (Met) have been well demonstrated."	1.46	Synergistic Chemopreventive and Therapeutic Effects of Co-drug UA-Met: Implication in Tumor Metastasis. ( Chen, X; Jiang, K; Shao, J; Shen, Z; Wu, P; Xu, A; Yang, X; Zheng, G, 2017)
"Herein, we reveal that breast cancer cells that preferentially metastasize to the lung or bone display relatively high expression of PGC-1α compared with those that metastasize to the liver."	1.46	PGC-1α Promotes Breast Cancer Metastasis and Confers Bioenergetic Flexibility against Metabolic Drugs. ( Andrzejewski, S; Annis, MG; Chénard, V; Johnson, RM; Klimcakova, E; McGuirk, S; Northey, JJ; Papadopoli, DJ; Siegel, PM; Sriram, U; St-Pierre, J; Tabariès, S, 2017)
"Recurrences, metastases, secondary cancers, survival and carcinoembryonic antigen levels were compared using t test and chi-squared test."	1.46	Metformin Has Positive Therapeutic Effects in Colon Cancer and Lung Cancer. ( Frieson, D; Henderson, D; Solomon, SS; Zuber, J, 2017)
"Treatment with metformin reduced STAT3-phosphorylation in all investigated BTICs and TCs."	1.46	Stattic and metformin inhibit brain tumor initiating cells by reducing STAT3-phosphorylation. ( Bogdahn, U; Hau, P; Leidgens, V; Moeckel, S; Proescholdt, M; Proske, J; Rauer, L; Renner, K; Riemenschneider, MJ; Seliger, C; Vollmann-Zwerenz, A, 2017)
"We propose that metformin represses prostate cancer EMT and metastasis through targeting the COX2/PGE2/STAT3 axis."	1.46	Metformin inhibits castration-induced EMT in prostate cancer by repressing COX2/PGE2/STAT3 axis. ( Jiang, J; Jiang, Y; Lan, W; Liu, G; Liu, Q; Tong, D; Xiao, H; Xu, J; Zhang, D, 2017)
"Diabetic men have lowered overall prostate cancer (PCa) risk, while their risk of high-grade disease may be elevated."	1.46	Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. ( Auvinen, A; Haring, A; Murtola, TJ; Taari, K; Talala, K; Tammela, TL, 2017)
" Limitations include retrospective design and lack of data on metformin dosage and duration of use."	1.43	Metformin Use in Relation With Survival Outcomes of Patients With Renal Cell Carcinoma. ( Cheng, JJ; Kanesvaran, R; Li, H; Ng, LG; Ng, QS; Tan, HS; Tan, MH; Tan, PH; Toh, CK, 2016)
"102 women with newly diagnosed breast cancer were divided into 2 main groups, a control group and a metformin group."	1.43	Metformin may protect nondiabetic breast cancer women from metastasis. ( El-Bassiouny, NA; El-Haggar, SM; El-Shitany, NA; Mostafa, MF, 2016)
"Metformin is a safe, well-tolerated, inexpensive treatment that can be given in addition to current standard-of-care therapies for prostate cancer."	1.43	Repurposing Metformin as Therapy for Prostate Cancer within the STAMPEDE Trial Platform. ( Adler, A; Clarke, N; Gillessen, S; Gilson, C; James, N; Sydes, MR, 2016)
"Metformin is an oral drug that has been widely used to treat type 2 diabetes mellitus."	1.42	Metformin inhibits the proliferation, metastasis, and cancer stem-like sphere formation in osteosarcoma MG63 cells in vitro. ( Chen, X; Hu, C; Hu, F; Shen, Y; Wang, J; Yu, P; Zhang, W, 2015)
"Metformin greatly reduced the number of metastases of Lewis lung cancer without affecting tumor growth."	1.42	Metformin prevents cancer metastasis by inhibiting M2-like polarization of tumor associated macrophages. ( Chen, H; Ding, L; He, Q; Liang, G; Liu, R; Wu, H; Yang, B; Yao, Z; Zhang, J; Zhou, Y, 2015)
"This drug was also used in the treatment of polycystic ovarian syndrome and recent reports indicate the possibility of using this drug in oncology."	1.39	[Metformin--new treatment strategies for gynecologic neoplasms]. ( Kiałka, M; Krzysiek, J; Milewicz, T; Mrozińska, S; Ociepka, A, 2013)
"Hematogeneous metastasis can occur via a cascade of circulating tumor cell adhesion events to the endothelial lining of the vasculature, i."	1.39	Phenotypic switch in blood: effects of pro-inflammatory cytokines on breast cancer cell aggregation and adhesion. ( Chandrasekaran, S; Geng, Y; Gidwani, M; Hsu, JW; Hughes, AD; King, MR, 2013)
"Hence, the control or destruction of cancer stem cells should be a major goal of cancer management."	1.38	Metformin may antagonize Lin28 and/or Lin28B activity, thereby boosting let-7 levels and antagonizing cancer progression. ( McCarty, MF, 2012)
"Ovarian cancer is the most lethal gynecologic cancer in women."	1.37	Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. ( Giri, S; Graham, RP; Maguire, JL; Rattan, R; Shridhar, V, 2011)
"We also immuno-stained human breast cancers for a series of well-established protein biomarkers of metabolism."	1.37	Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: visualizing the therapeutic effects of metformin in tumor tissue. ( Birbe, RC; Broda, P; Ertel, A; Flomenberg, N; Howell, A; Lisanti, MP; Martinez-Outschoorn, UE; Minetti, C; Pavlides, S; Pestell, RG; Sotgia, F; Tsirigos, A; Whitaker-Menezes, D; Witkiewicz, AK, 2011)

Research

Studies (75)

Authors

Clinical Trials (3)

Trial Overview

Trial Outcomes

Overall Survial

Timeframe	Studies, this research(%)	All Research%
pre-1990	2 (2.67)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	55 (73.33)	24.3611
2020's	18 (24.00)	2.80

Authors	Studies
Lusica, PMM	1
Eugenio, KPY	1
Sacdalan, DBL	1
Jimeno, CA	1
Heishima, K	1
Sugito, N	1
Soga, T	1
Nishikawa, M	1
Ito, Y	1
Honda, R	1
Kuranaga, Y	1
Sakai, H	1
Ito, R	1
Nakagawa, T	1
Ueda, H	1
Akao, Y	1
Teufelsbauer, M	1
Lang, C	1
Plangger, A	1
Rath, B	1
Moser, D	1
Staud, C	1
Radtke, C	1
Neumayer, C	1
Hamilton, G	1
Suwei, D	1
Yanbin, X	1
Jianqiang, W	1
Xiang, M	1
Zhuohui, P	1
Jianping, K	1
Yunqing, W	1
Zhen, L	1
Hirayama, T	1
Nagata, Y	1
Nishida, M	1
Matsuo, M	1
Kobayashi, S	1
Yoneda, A	1
Kanetaka, K	1
Udono, H	1
Eguchi, S	1
Bae, WJ	1
Ahn, JM	1
Byeon, HE	1
Kim, S	1
Lee, D	1
Hakimee, H	1
Hutamekalin, P	1
Tanasawet, S	1
Chonpathompikunlert, P	1
Tipmanee, V	1
Sukketsiri, W	1
Jin, D	1
Guo, J	2
Wu, Y	1
Chen, W	1
Du, J	1
Yang, L	2
Wang, X	1
Gong, K	1
Dai, J	1
Miao, S	1
Li, X	2
Su, G	1
Gong, Y	2
Wang, C	2
Jiang, Y	2
Zhang, S	1
Feng, S	1
Fu, Y	1
Luo, Y	2
Chen, ZX	1
Liu, MD	1
Guo, DK	1
Zou, MZ	1
Wang, SB	1
Cheng, H	2
Zhong, Z	1
Zhang, XZ	1
Liu, J	1
Li, J	2
Chen, H	3
Wang, R	1
Li, P	1
Miao, Y	1
Liu, P	1
Fan, Z	1
Huang, Q	1
Yang, C	1
Jin, K	1
Fan, K	1
Ni, Q	1
Yu, X	1
Luo, G	1
Liu, C	1
Li, S	1
Zhu, H	1
Xia, J	1
Zhang, F	1
Xu, R	1
Lin, Q	1
Saito, A	1
Kitayama, J	1
Horie, H	1
Koinuma, K	1
Ohzawa, H	1
Yamaguchi, H	1
Kawahira, H	1
Mimura, T	1
Lefor, AK	1
Sata, N	1
Kawakita, E	1
Yang, F	1
Kumagai, A	1
Takagaki, Y	1
Kitada, M	1
Yoshitomi, Y	1
Ikeda, T	1
Nakamura, Y	1
Ishigaki, Y	1
Kanasaki, K	1
Koya, D	1
Kim, HS	1
Kim, JH	1
Jang, HJ	1
Lee, J	1
Dang, J	1
Gao, J	3
Ma, F	2
Wang, J	3
Wang, D	1
Li, W	1
Sun, H	3
Li, L	2
Liu, X	1
Hu, D	1
Jin, Z	1
Marciano, O	1
Mehazri, L	1
Shpungin, S	1
Varvak, A	1
Zacksenhaus, E	1
Nir, U	1
Yang, J	1
Fang, HJ	1
Cao, Q	1
Mao, ZW	1
Yenmis, G	1
Yaprak Sarac, E	1
Besli, N	1
Soydas, T	1
Tastan, C	1
Dilek Kancagi, D	1
Yilanci, M	1
Senol, K	1
Karagulle, OO	1
Ekmekci, CG	1
Ovali, E	1
Tuncdemir, M	1
Ulutin, T	1
Kanigur Sultuybek, G	1
Abrams, SL	1
Akula, SM	1
Meher, AK	1
Steelman, LS	1
Gizak, A	1
Duda, P	1
Rakus, D	1
Martelli, AM	1
Ratti, S	1
Cocco, L	1
Montalto, G	1
Cervello, M	1
Ruvolo, P	1
Libra, M	1
Falzone, L	1
Candido, S	1
McCubrey, JA	1
Valaee, S	1
Yaghoobi, MM	1
Shamsara, M	1
Nurani, M	1
Akbari, V	1
Taheri, A	1
Li, T	2
Liu, Z	1
Gou, S	1
Zhang, HH	1
Zhang, Y	1
Cheng, YN	1
Gong, FL	1
Cao, ZQ	1
Yu, LG	1
Guo, XL	1
Henderson, D	1
Frieson, D	1
Zuber, J	1
Solomon, SS	1
Andrzejewski, S	1
Klimcakova, E	1
Johnson, RM	1
Tabariès, S	1
Annis, MG	1
McGuirk, S	1
Northey, JJ	1
Chénard, V	1
Sriram, U	1
Papadopoli, DJ	1
Siegel, PM	1
St-Pierre, J	1
Zheng, G	1
Shen, Z	1
Xu, A	1
Jiang, K	1
Wu, P	1
Yang, X	1
Chen, X	2
Shao, J	1
Dogan Turacli, I	1
Umudum, H	1
Pampal, A	1
Candar, T	1
Kavasoglu, L	1
Sari, Y	1
Marrone, KA	2
Zhou, X	1
Forde, PM	1
Purtell, M	1
Brahmer, JR	2
Hann, CL	1
Kelly, RJ	1
Coleman, B	1
Gabrielson, E	1
Rosner, GL	1
Ettinger, DS	2
Antognelli, C	1
Cecchetti, R	1
Riuzzi, F	1
Peirce, MJ	1
Talesa, VN	1
Song, L	1
Chang, R	1
Peng, X	1
Xu, X	1
Zhan, X	1
Zhan, L	1
Yang, Q	1
Guo, X	1
Bao, X	1
Zhao, L	1
Guan, H	1
Li, F	1
Noh, Y	1
Jeon, SM	1
Shin, S	1
Jian, Z	1
Cheng, T	1
Zhang, Z	1
Raulefs, S	1
Shi, K	1
Steiger, K	1
Maeritz, N	1
Kleigrewe, K	1
Hofmann, T	1
Benitz, S	1
Bruns, P	1
Lamp, D	1
Jastroch, M	1
Akkan, J	1
Jäger, C	1
Huang, P	1
Nie, S	1
Shen, S	1
Zou, X	1
Ceyhan, GO	1
Michalski, CW	1
Friess, H	1
Kleeff, J	1
Kong, B	1
Kang, S	1
Kim, BR	1
Kang, MH	1
Kim, DY	1
Lee, DH	1
Oh, SC	1
Min, BW	1
Um, JW	1
Ranasinghe, WKB	1
Williams, S	1
Ischia, J	1
Wetherell, D	1
Baldwin, G	1
Shulkes, A	1
Sengupta, S	1
Bolton, D	1
Patel, O	1
Jiang, T	1
Chen, L	1
Huang, Y	1
Xu, M	1
Zhou, S	1
Gu, X	1
Chen, Y	1
Liang, K	1
Pei, Y	1
Song, Q	1
Liu, S	1
Lu, H	1
Gao, X	1
Chen, J	2
Parikh, AB	1
Becker, DJ	1
Levy, BP	1
Cerezo, M	1
Tichet, M	1
Abbe, P	1
Ohanna, M	1
Lehraiki, A	1
Rouaud, F	1
Allegra, M	1
Giacchero, D	1
Bahadoran, P	1
Bertolotto, C	1
Tartare-Deckert, S	1
Ballotti, R	1
Rocchi, S	1
Milewicz, T	1
Kiałka, M	1
Mrozińska, S	1
Ociepka, A	1
Krzysiek, J	1
Mao, Y	1
Xia, R	1
Wang, L	1
Wang, YQ	1
Gao, FB	1
Spillane, S	1
Bennett, K	1
Sharp, L	1
Barron, TI	1
Reddi, A	1
Powers, MA	1
Dellavalle, RP	1
Oliveras-Ferraros, C	1
Vazquez-Martin, A	1
Cuyàs, E	1
Corominas-Faja, B	1
Rodríguez-Gallego, E	1
Fernández-Arroyo, S	1
Martin-Castillo, B	1
Joven, J	1
Menendez, JA	1
Zhao, Z	1
Cheng, X	1
Wang, Y	1
Han, R	1
Xiang, T	1
He, L	1
Long, H	1
Zhu, B	1
He, Y	1
Babcook, MA	1
Shukla, S	1
Fu, P	1
Vazquez, EJ	1
Puchowicz, MA	1
Molter, JP	1
Oak, CZ	1
MacLennan, GT	1
Flask, CA	1
Lindner, DJ	1
Parker, Y	1
Daneshgari, F	1
Gupta, S	1
Orecchioni, S	2
Reggiani, F	2
Talarico, G	2
Mancuso, P	2
Calleri, A	2
Gregato, G	2
Labanca, V	2
Noonan, DM	2
Dallaglio, K	2
Albini, A	2
Bertolini, F	2
Dirat, B	1
Ader, I	1
Golzio, M	1
Massa, F	1
Mettouchi, A	1
Laurent, K	1
Larbret, F	1
Malavaud, B	1
Cormont, M	1
Lemichez, E	1
Cuvillier, O	1
Tanti, JF	1
Bost, F	1
Kim, HJ	2
Kwon, H	1
Lee, JW	1
Lee, SB	1
Park, HS	1
Sohn, G	1
Lee, Y	1
Koh, BS	1
Yu, JH	1
Son, BH	1
Ahn, SH	1
Hu, C	1
Zhang, W	3
Shen, Y	1
Hu, F	1
Yu, P	1
Giannoni, E	1
Taddei, ML	1
Morandi, A	1
Comito, G	1
Calvani, M	1
Bianchini, F	1
Richichi, B	1
Raugei, G	1
Wong, N	1
Tang, D	1
Chiarugi, P	1
Ding, L	1
Liang, G	1
Yao, Z	1
Zhang, J	1
Liu, R	1
Zhou, Y	1
Wu, H	1
Yang, B	1
He, Q	1
Rossi, T	1
Guo, Z	2
Cao, M	2
You, A	2
Zhou, H	2
Li, H	3
Cui, Y	2
Fang, F	2
Song, T	2
Li, Q	2
Zhu, X	2
Zhang, T	2
Cheng, JJ	1
Tan, HS	1
Tan, PH	1
Ng, LG	1
Ng, QS	1
Toh, CK	1
Kanesvaran, R	1
Tan, MH	1
El-Haggar, SM	1
El-Shitany, NA	1
Mostafa, MF	1
El-Bassiouny, NA	1
Zuo, B	1
Yin, H	1
Jacob, L	1
Kostev, K	1
Rathmann, W	1
Kalder, M	1
Keizman, D	1
Ish-Shalom, M	1
Sella, A	1
Gottfried, M	1
Maimon, N	1
Peer, A	1
Hammers, H	1
Eisenberger, MA	1
Sinibaldi, V	1
Neiman, V	1
Rosenbaum, E	1
Sarid, D	1
Mermershtain, W	1
Rouvinov, K	1
Berger, R	1
Carducci, MA	1
Gillessen, S	1
Gilson, C	1
James, N	1
Adler, A	1
Sydes, MR	1
Clarke, N	1
Hamieh, L	1
McKay, RR	1
Lin, X	1
Moreira, RB	1
Simantov, R	1
Choueiri, TK	1
Shen, C	1
Peng, C	1
Shen, B	1
Zhu, Z	1
Xu, N	1
Xie, J	1
Leidgens, V	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomized Phase II Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Previously Untreated Advanced/Metastatic Pulmonary Adenocarcinoma[NCT01578551]	Phase 2	25 participants (Actual)	Interventional	2012-05-31	Terminated (stopped due to Low enrollment)
STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled Trial[NCT00268476]	Phase 2/Phase 3	11,992 participants (Actual)	Interventional	2005-07-08	Active, not recruiting
Caffeic Acid for Advanced Esophageal Squamous Cell Cancer: A Randomized, Double-blind, and Multicenter Trial in Chinese Patients[NCT03070262]	Phase 3	300 participants (Anticipated)	Interventional	2017-01-31	Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Number of months alive after 1 year of the combination of metformin with standard chemotherapy in patients with previously untreated advanced or metastatic pulmonary adenocarcinoma. (NCT01578551)
Timeframe: up to 2 years

Progression Free Survival (PFS)

Intervention	months (Median)
Arm A	15.9
Arm B	13.9

Number of months without evidence of progression after 1 year of the combination of metformin and standard chemotherapy in patients with previously untreated advanced or metastatic pulmonary adenocarcinoma. (NCT01578551)
Timeframe: 1 year

Response to Therapy

Intervention	months (Median)
Arm A	9.6
Arm B	6.7

Percentage of participants with complete or partial response to combination of metformin with standard chemotherapy in patients with previously untreated advanced or metastatic pulmonary adenocarcinoma as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (NCT01578551)
Timeframe: 2 years

Article	Year
A systematic review and meta-analysis on the efficacy and safety of metformin as adjunctive therapy among women with metastatic breast cancer. Cancer treatment and research communications, 2021, Volume: 29 Topics: Breast Neoplasms; Female; Humans; Metformin; Neoplasm Metastasis; Randomized Controlled Trials as To	2021
The addition of metformin to systemic anticancer therapy in advanced or metastatic cancers: a meta-analysis of randomized controlled trials. International journal of medical sciences, 2020, Volume: 17, Issue:16 Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Metformin; Neoplasm Metastasis; Neoplasm Sta	2020
The effect of metformin on survival of patients with pancreatic cancer: a meta-analysis. Scientific reports, 2017, 07-19, Volume: 7, Issue:1 Topics: Humans; Metformin; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Publication Bias; Su	2017

Article	Year
A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy-Naïve Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer. The oncologist, 2018, Volume: 23, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, No	2018
A pooled analysis of two phase II trials evaluating metformin plus platinum-based chemotherapy in advanced non-small cell lung cancer. Cancer treatment and research communications, 2019, Volume: 20 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female;	2019

Article	Year
Petasin potently inhibits mitochondrial complex I-based metabolism that supports tumor growth and metastasis. The Journal of clinical investigation, 2021, 09-01, Volume: 131, Issue:17 Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Electron Trans	2021
Effects of metformin on human bone-derived mesenchymal stromal cell-breast cancer cell line interactions. Medical oncology (Northwood, London, England), 2022, Feb-12, Volume: 39, Issue:5 Topics: Adipokines; Breast Neoplasms; Cell Line, Tumor; Cell Migration Assays; Cell Proliferation; Culture M	2022
Metformin inhibits melanoma cell metastasis by suppressing the miR-5100/SPINK5/STAT3 axis. Cellular & molecular biology letters, 2022, Jun-15, Volume: 27, Issue:1 Topics: Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Epithelial-Mesenchymal Transition; Gen	2022
Metformin Prevents Peritoneal Dissemination Anticancer research, 2019, Volume: 39, Issue:9 Topics: Animals; Biomarkers; Cell Line, Tumor; Disease Models, Animal; Humans; Immunomodulation; Immunopheno	2019
PTPRD-inactivation-induced CXCL8 promotes angiogenesis and metastasis in gastric cancer and is inhibited by metformin. Journal of experimental & clinical cancer research : CR, 2019, Dec-05, Volume: 38, Issue:1 Topics: Cell Line, Tumor; Down-Regulation; Gene Silencing; Humans; Hypoglycemic Agents; Interleukin-8; Metfo	2019
Metformin Inhibit Cervical Cancer Migration by Suppressing the FAK/Akt Signaling Pathway. Asian Pacific journal of cancer prevention : APJCP, 2019, Dec-01, Volume: 20, Issue:12 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Female; Focal Adhesion Kinase 1; HeLa Cells;	2019
Metformin-repressed miR-381-YAP-snail axis activity disrupts NSCLC growth and metastasis. Journal of experimental & clinical cancer research : CR, 2020, Jan-06, Volume: 39, Issue:1 Topics: A549 Cells; Adult; Aged; Aged, 80 and over; Animals; Carcinoma, Non-Small-Cell Lung; Cell Cycle Prot	2020
Metformin Inhibits Tumor Metastasis through Suppressing Hsp90α Secretion in an AMPKα1-PKCγ Dependent Manner. Cells, 2020, 01-07, Volume: 9, Issue:1 Topics: Adenylate Kinase; Animals; Cell Membrane; HSP90 Heat-Shock Proteins; Humans; MCF-7 Cells; Metformin;	2020
A MSN-based tumor-targeted nanoplatform to interfere with lactate metabolism to induce tumor cell acidosis for tumor suppression and anti-metastasis. Nanoscale, 2020, Feb-07, Volume: 12, Issue:5 Topics: Antineoplastic Agents; Cell Line, Tumor; Fluvastatin; Folic Acid; Humans; Lactates; Manganese Compou	2020
Metformin suppresses proliferation and invasion of drug-resistant breast cancer cells by activation of the Hippo pathway. Journal of cellular and molecular medicine, 2020, Volume: 24, Issue:10 Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell N	2020
Diabetes Is Associated With the Metastasis of Pancreatic Neuroendocrine Tumors. Pancreas, 2020, Volume: 49, Issue:6 Topics: China; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Male;	2020
Glucose promotes epithelial-mesenchymal transitions in bladder cancer by regulating the functions of YAP1 and TAZ. Journal of cellular and molecular medicine, 2020, Volume: 24, Issue:18 Topics: Adaptor Proteins, Signal Transducing; Animals; Cell Line, Tumor; Cell Proliferation; Culture Media;	2020
Metformin changes the immune microenvironment of colorectal cancer in patients with type 2 diabetes mellitus. Cancer science, 2020, Volume: 111, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Female; Humans; Hyp	2020
Metformin Mitigates DPP-4 Inhibitor-Induced Breast Cancer Metastasis via Suppression of mTOR Signaling. Molecular cancer research : MCR, 2021, Volume: 19, Issue:1 Topics: Animals; Breast Neoplasms; Dipeptidyl Peptidase 4; Female; Gene Expression Profiling; Humans; Metfor	2021
Roles of metformin-mediated girdin expression in metastasis of epithelial ovarian cancer. Cell biology international, 2021, Volume: 45, Issue:5 Topics: Adult; Animals; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Movement; Cell Proliferation;	2021
Fer and FerT Govern Mitochondrial Susceptibility to Metformin and Hypoxic Stress in Colon and Lung Carcinoma Cells. Cells, 2021, 01-07, Volume: 10, Issue:1 Topics: Cell Hypoxia; Cell Line, Tumor; Colonic Neoplasms; Humans; Lung Neoplasms; Metformin; Mitochondria;	2021
The design of cyclometalated iridium(iii)-metformin complexes for hypoxic cancer treatment. Chemical communications (Cambridge, England), 2021, Jan-28, Volume: 57, Issue:9 Topics: Antineoplastic Agents; Cell Line; Cisplatin; Coordination Complexes; Humans; Iridium; Metformin; Neo	2021
Anti-cancer effect of metformin on the metastasis and invasion of primary breast cancer cells through mediating NF-kB activity. Acta histochemica, 2021, Volume: 123, Issue:4 Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Metformin; Middle Aged; Neoplasm Invasivene	2021
GSK-3β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals. Cells, 2021, 04-06, Volume: 10, Issue:4 Topics: Adenocarcinoma; Adenylate Kinase; Antineoplastic Agents; bcl-X Protein; Berberine; Biphenyl Compound	2021
Metformin inhibits gastric cancer cells metastatic traits through suppression of epithelial-mesenchymal transition in a glucose-independent manner. PloS one, 2017, Volume: 12, Issue:3 Topics: beta Catenin; Cadherins; Cell Line, Tumor; Cell Movement; Epithelial-Mesenchymal Transition; Gene Ex	2017
Preparation and characterization of metformin surface modified cellulose nanofiber gel and evaluation of its anti-metastatic potentials. Carbohydrate polymers, 2017, Jun-01, Volume: 165 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cellulose; Gels; Melanoma, Experime	2017
Metformin incombination with curcumin inhibits the growth, metastasis, and angiogenesis of hepatocellular carcinoma in vitro and in vivo. Molecular carcinogenesis, 2018, Volume: 57, Issue:1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line; Cell	2018
Metformin Has Positive Therapeutic Effects in Colon Cancer and Lung Cancer. The American journal of the medical sciences, 2017, Volume: 354, Issue:3 Topics: Aged; Antineoplastic Agents; Cohort Studies; Colonic Neoplasms; Diabetes Mellitus, Type 2; Disease-F	2017
PGC-1α Promotes Breast Cancer Metastasis and Confers Bioenergetic Flexibility against Metabolic Drugs. Cell metabolism, 2017, Nov-07, Volume: 26, Issue:5 Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Energy Metabolism; Female; Humans; Hypog	2017
Synergistic Chemopreventive and Therapeutic Effects of Co-drug UA-Met: Implication in Tumor Metastasis. Journal of agricultural and food chemistry, 2017, Dec-20, Volume: 65, Issue:50 Topics: Animals; Cadherins; Cell Line, Tumor; Drug Synergism; Female; Humans; Metformin; Mice; Neoplasm Meta	2017
Do MCF7 cells cope with metformin treatment under energetic stress in low glucose conditions? Molecular biology reports, 2018, Volume: 45, Issue:3 Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Galectin 3	2018
Glyoxalase 1 sustains the metastatic phenotype of prostate cancer cells via EMT control. Journal of cellular and molecular medicine, 2018, Volume: 22, Issue:5 Topics: 3' Untranslated Regions; Aged; Base Sequence; Cell Line, Tumor; Cell Movement; Epithelial-Mesenchyma	2018
LKB1 obliterates Snail stability and inhibits pancreatic cancer metastasis in response to metformin treatment. Cancer science, 2018, Volume: 109, Issue:5 Topics: AMP-Activated Protein Kinase Kinases; Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell	2018
Metformin Enhances the Effect of Regorafenib and Inhibits Recurrence and Metastasis of Hepatic Carcinoma After Liver Resection via Regulating Expression of Hypoxia Inducible Factors 2α (HIF-2α) and 30 kDa HIV Tat-Interacting Protein (TIP30). Medical science monitor : international medical journal of experimental and clinical research, 2018, Apr-14, Volume: 24 Topics: Acetyltransferases; Animals; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Hep	2018
Inhibition of LCMR1 and ATG12 by demethylation-activated miR-570-3p is involved in the anti-metastasis effects of metformin on human osteosarcoma. Cell death & disease, 2018, 05-23, Volume: 9, Issue:6 Topics: Adolescent; Adult; Animals; Autophagy; Autophagy-Related Protein 12; Base Sequence; Cell Line, Tumor	2018
Association between glucose-lowering treatment and cancer metastasis among patients with preexisting type 2 diabetes and incident malignancy. International journal of cancer, 2019, 04-01, Volume: 144, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Comorbidity; Diabetes Mellitus, Type 2; Dipeptidyl-P	2019
Glycemic Variability Promotes Both Local Invasion and Metastatic Colonization by Pancreatic Ductal Adenocarcinoma. Cellular and molecular gastroenterology and hepatology, 2018, Volume: 6, Issue:4 Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Collagen Type VI; Core	2018
Anti-metastatic effect of metformin via repression of interleukin 6-induced epithelial-mesenchymal transition in human colon cancer cells. PloS one, 2018, Volume: 13, Issue:10 Topics: Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Epithelial	2018
Metformin may offer no protective effect in men undergoing external beam radiation therapy for prostate cancer. BJU international, 2019, Volume: 123 Suppl 5 Topics: Adenocarcinoma; Androgen Antagonists; Cell Survival; Diabetes Mellitus, Type 2; Humans; Hypoglycemic	2019
Metformin and Docosahexaenoic Acid Hybrid Micelles for Premetastatic Niche Modulation and Tumor Metastasis Suppression. Nano letters, 2019, 06-12, Volume: 19, Issue:6 Topics: Animals; Anti-Inflammatory Agents; Docosahexaenoic Acids; Lung; Metformin; Mice; Micelles; Neoplasm	2019
Metformin blocks melanoma invasion and metastasis development in AMPK/p53-dependent manner. Molecular cancer therapeutics, 2013, Volume: 12, Issue:8 Topics: AMP-Activated Protein Kinases; Animals; Cell Line, Tumor; Cell Movement; Disease Models, Animal; Enz	2013
[Metformin--new treatment strategies for gynecologic neoplasms]. Przeglad lekarski, 2013, Volume: 70, Issue:2 Topics: Antineoplastic Agents; Drug Synergism; Female; Genital Neoplasms, Female; Humans; Lactoylglutathione	2013
Multimodality imaging assessments of response to metformin therapy for breast cancer in nude mice. Chinese medical journal, 2013, Volume: 126, Issue:19 Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Diffusion Magnetic Resonance Imagin	2013
Metformin exposure and disseminated disease in patients with colorectal cancer. Cancer epidemiology, 2014, Volume: 38, Issue:1 Topics: Aged; Aged, 80 and over; Colorectal Neoplasms; Databases, Factual; Dose-Response Relationship, Drug;	2014
Therapeutic potential of the anti-diabetic agent metformin in targeting the skin cancer stem cell diaspora. Experimental dermatology, 2014, Volume: 23, Issue:5 Topics: Chemoprevention; Diabetes Complications; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Mel	2014
Acquired resistance to metformin in breast cancer cells triggers transcriptome reprogramming toward a degradome-related metastatic stem-like profile. Cell cycle (Georgetown, Tex.), 2014, Volume: 13, Issue:7 Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Breast Neoplasms; Drug Resistance, Neoplasm; G	2014
Metformin inhibits the IL-6-induced epithelial-mesenchymal transition and lung adenocarcinoma growth and metastasis. PloS one, 2014, Volume: 9, Issue:4 Topics: Adenocarcinoma; Blotting, Western; Cell Division; Cell Line, Tumor; Enzyme-Linked Immunosorbent Assa	2014
Synergistic simvastatin and metformin combination chemotherapy for osseous metastatic castration-resistant prostate cancer. Molecular cancer therapeutics, 2014, Volume: 13, Issue:10 Topics: Animals; Anticholesteremic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; C	2014
The biguanides metformin and phenformin inhibit angiogenesis, local and metastatic growth of breast cancer by targeting both neoplastic and microenvironment cells. International journal of cancer, 2015, Mar-15, Volume: 136, Issue:6 Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Electron Tran	2015
Inhibition of the GTPase Rac1 mediates the antimigratory effects of metformin in prostate cancer cells. Molecular cancer therapeutics, 2015, Volume: 14, Issue:2 Topics: Actin Cytoskeleton; Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chemokine CXCL12;	2015
Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes. Breast cancer research : BCR, 2015, May-03, Volume: 17 Topics: Adult; Aged; Breast Neoplasms; Diabetes Mellitus; Female; Humans; Immunohistochemistry; Kaplan-Meier	2015
Metformin inhibits the proliferation, metastasis, and cancer stem-like sphere formation in osteosarcoma MG63 cells in vitro. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2015, Volume: 36, Issue:12 Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell	2015
Targeting stromal-induced pyruvate kinase M2 nuclear translocation impairs oxphos and prostate cancer metastatic spread. Oncotarget, 2015, Sep-15, Volume: 6, Issue:27 Topics: Active Transport, Cell Nucleus; Animals; Binding Sites; Carcinoma; Carrier Proteins; Cell Line, Tumo	2015
Metformin prevents cancer metastasis by inhibiting M2-like polarization of tumor associated macrophages. Oncotarget, 2015, Nov-03, Volume: 6, Issue:34 Topics: Animals; Carcinoma, Lewis Lung; Cell Line, Tumor; Cell Polarity; Macrophages; Metformin; Mice; Mice,	2015
Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells. Scientific reports, 2016, Jan-05, Volume: 6 Topics: Adipose Tissue, White; AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Apoptosis; Asp	2016
Metformin inhibits the prometastatic effect of sorafenib in hepatocellular carcinoma by upregulating the expression of TIP30. Cancer science, 2016, Volume: 107, Issue:4 Topics: Acetyltransferases; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Gene E	2016
Metformin Use in Relation With Survival Outcomes of Patients With Renal Cell Carcinoma. Clinical genitourinary cancer, 2016, Volume: 14, Issue:2 Topics: Aged; Carcinoma, Renal Cell; Diabetes Mellitus; Female; Humans; Kidney Neoplasms; Male; Metformin; M	2016
Metformin may protect nondiabetic breast cancer women from metastasis. Clinical & experimental metastasis, 2016, Volume: 33, Issue:4 Topics: Adult; Aged; Blood Glucose; Breast Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans	2016
Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models. Journal of hematology & oncology, 2016, Mar-08, Volume: 9 Topics: Acetyltransferases; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;	2016
Impact of metformin on metastases in patients with breast cancer and type 2 diabetes. Journal of diabetes and its complications, 2016, Volume: 30, Issue:6 Topics: Aged; Aged, 80 and over; Breast Neoplasms; Diabetes Mellitus, Type 2; Female; Germany; Humans; Hypog	2016
Metformin Use and Outcome of Sunitinib Treatment in Patients With Diabetes and Metastatic Renal Cell Carcinoma. Clinical genitourinary cancer, 2016, Volume: 14, Issue:5 Topics: Aged; Aged, 80 and over; Carcinoma, Renal Cell; Comorbidity; Diabetes Mellitus; Disease-Free Surviva	2016
Repurposing Metformin as Therapy for Prostate Cancer within the STAMPEDE Trial Platform. European urology, 2016, Volume: 70, Issue:6 Topics: Androgen Antagonists; Drug Repositioning; Drug Therapy, Combination; Humans; Hyperglycemia; Hypoglyc	2016
Effect of Metformin Use on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma. Clinical genitourinary cancer, 2017, Volume: 15, Issue:2 Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, P	2017
Sirolimus and metformin synergistically inhibit hepatocellular carcinoma cell proliferation and improve long-term survival in patients with HCC related to hepatitis B virus induced cirrhosis after liver transplantation. Oncotarget, 2016, Sep-20, Volume: 7, Issue:38 Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line	2016
Stattic and metformin inhibit brain tumor initiating cells by reducing STAT3-phosphorylation. Oncotarget, 2017, Jan-31, Volume: 8, Issue:5 Topics: Adult; Aged; AMP-Activated Protein Kinases; Animals; Antineoplastic Combined Chemotherapy Protocols;	2017
Metformin inhibits castration-induced EMT in prostate cancer by repressing COX2/PGE2/STAT3 axis. Cancer letters, 2017, 03-28, Volume: 389 Topics: Aged; Animals; Cell Line, Tumor; Cell Movement; Cyclooxygenase 2 Inhibitors; Dinoprostone; Epithelia	2017
Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. Scandinavian journal of urology, 2017, Volume: 51, Issue:1 Topics: Aged; Diabetes Mellitus; Dose-Response Relationship, Drug; Early Detection of Cancer; Finland; Human	2017
Caffeic Acid Expands Anti-Tumor Effect of Metformin in Human Metastatic Cervical Carcinoma HTB-34 Cells: Implications of AMPK Activation and Impairment of Fatty Acids De Novo Biosynthesis. International journal of molecular sciences, 2017, Feb-21, Volume: 18, Issue:2 Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Caffeic Acids; Cell Cycle; Cell Lin	2017
Metformin treatment exerts antiinvasive and antimetastatic effects in human endometrial carcinoma cells. The Journal of clinical endocrinology and metabolism, 2011, Volume: 96, Issue:3 Topics: Adult; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Movement; Cyclic AMP; Cyclic	2011
Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Neoplasia (New York, N.Y.), 2011, Volume: 13, Issue:5 Topics: AMP-Activated Protein Kinases; Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Cell Proliferatio	2011
Metformin may antagonize Lin28 and/or Lin28B activity, thereby boosting let-7 levels and antagonizing cancer progression. Medical hypotheses, 2012, Volume: 78, Issue:2 Topics: Animals; DNA-Binding Proteins; Histone Deacetylase Inhibitors; Humans; Metformin; Mice; MicroRNAs; N	2012
Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: visualizing the therapeutic effects of metformin in tumor tissue. Cell cycle (Georgetown, Tex.), 2011, Dec-01, Volume: 10, Issue:23 Topics: Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Computational Biology; Electron Transport Com	2011
Phenotypic switch in blood: effects of pro-inflammatory cytokines on breast cancer cell aggregation and adhesion. PloS one, 2013, Volume: 8, Issue:1 Topics: Anti-Inflammatory Agents; Breast Neoplasms; Cell Adhesion; Cell Aggregation; Cell Line, Tumor; Cell	2013
Fibrinolytic activity and haemagglutination inhibition immunoassays. Scandinavian journal of haematology, 1970, Volume: 7, Issue:4 Topics: Adult; Aged; Biguanides; Clofibrate; Coronary Disease; Ethylestrenol; Female; Fibrin; Fibrinogen; Fi	1970
Pharmacological enhancement and short-term stimulation of blood fibrinolytic activity. Scandinavian journal of haematology, 1969, Volume: 6, Issue:6 Topics: Adolescent; Adult; Aged; Aminocaproates; Anticholesteremic Agents; Arteriosclerosis; Arthritis, Rheu	1969

metformin and Neoplasm Metastasis